Community-based Study Evaluating Blood Biomarkers for Alzheimers Disease Screening in Older Adults Aged 60 to 80

What this Trial Is About

Researchers are conducting a prospective, multicenter observational cohort study to evaluate blood-based biomarkers for Alzheimers disease AD screening in a real-world community setting among Chinese older adults aged 60 to 80. The study aims to determine the clinical value of biomarkers like phosphorylated tau 217 to amyloid 42 ratio pTau217A42 and glial fibrillary acidic protein GFAP for identifying AD in community-dwelling older adults. It also seeks to establish baseline levels and reference intervals of these biomarkers for this population. Participants are randomly enrolled from community-dwelling older adults undergoing routine physical exams or outpatient visits. All participants will have blood drawn for biomarker testing. Those with positive biomarker resultsdefined by abnormal pTau217A42 ratio andor GFAP levelswill complete a full set of cognitive tests including the Mini-Mental State Examination MMSE, Montreal Cognitive Assessment MoCA, Activities of Daily Living ADL scale, and 17-item Hamilton Depression Rating Scale HAMD-17. Additionally, 15% of participants with negative biomarker results will be randomly selected to complete the same cognitive assessments. Throughout the study, researchers will monitor blood biomarker levels at enrollment and follow cognitive function through standardized assessments. The study observes participants health and cognitive status without any assigned treatments or interventions. This observational approach allows for understanding the screening performance of these blood markers and their relation to cognitive function in older adults. Participation involves routine blood tests and cognitive questionnaires, with no study-specific treatments administered.

Community-based Screening for Alzheimer's Disease